Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features
Ting Duan, Mingxin Xu, Haibo Zhang, Shengchang Wu, Haochu Wang, Zhenying Guo · 2024
Read Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features by Ting Duan, Mingxin Xu, Haibo Zhang, Shengchang Wu, Haochu Wang, Zhenying Guo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11668654.txt.
Description
Ting Duan and five co-authors report long follow-up on a rare, aggressive chest tumor treated with surgery plus immune and targeted drugs. Their 2024 case report concerns a tumor defined by loss of the SMARCA4 gene. Such tumors grow fast, sit in the chest, and carry a typical survival of only four to seven months. No standard treatment exists.
Their patient, a 56-year-old non-smoker, first had the lung mass and nearby nodes removed, then standard chemotherapy. Five months later the disease spread to an adrenal gland, which was also removed. Gene reads showed losses across the SMARCA family and a very high mutation load. A pairing of pembrolizumab with anlotinib then began as second-line care. The report tracks the lasting response and the molecular features behind it.
Catalog record
| CREATOR | Ting Duan, Mingxin Xu, Haibo Zhang, Shengchang Wu, Haochu Wang, Zhenying Guo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |